Company: SINT
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024040
Chunk: 7

Company: Sintx Technologies, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 8
Chunk 7
---
 all of the issued and outstanding shares of TA&T in exchange for the assumption by Tethon
of the outstanding liabilities of TA&T. The disposal did not represent a strategic shift that will have a major effect on the Company’s
operations and financials and, therefore, did not qualify for discontinued operations treatment under ASC 205-20.

The
following table summarizes the carrying amounts of the major classes of assets and liabilities of TA&T at the date of sale that were
transferred to the Tethon (in thousands):

 Schedule of Major Classes of Assets
and Liabilities of TA & T at the Date of Sale

    February 19, 2025 
  
    Cash and cash equivalents 
    $4 
  
    Inventories 
     8 
  
    Accounts receivable 
     91 
  
    Right of use asset 
     376 
  
    Property and equipment, net 
     248 
  
    Other assets 
     16 
  
    Total assets sold 
     743 
  
    Accounts payable 
     (26)
  
    Accrued expenses 
     (275)
  
    Operating lease liability 
     (384)
  
    Other liabilities 
     (34)
  
    Total liabilities assumed 
     (719)
  
    Net assets sold 
    $24 

No
consideration was paid other than the assumption by Tethon of the above liabilities. No significant transaction costs were incurred.
No earnout or other contingent consideration arrangements were included in the Agreement.

    10

3.
Basic and Diluted Net Income (Loss) per Common Share

Basic
net income (loss) per share is calculated by dividing the net income (loss) by the weighted-average number of common shares outstanding
for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss
by the weighted-average number of common share equivalents outstanding for the period that are determined to be dilutive. Common stock
equivalents are primarily comprised of preferred stock and warrants for the purchase of common stock. The Company had potentially dilutive
securities of approximately 2.1 million and 0.1 million as of June 30, 2025, and 2024, respectively, that were not included in the fully
diluted loss per share calculation because they would have been antidilutive.

Below
are basic and diluted loss per share data for the three months ended June 30,